KROS Keros Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Keros Therapeutics, Inc. (KROS) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 4, 2026, a 10-Q quarterly report filed on May 14, 2026, an 8-K current report filed on August 3, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Keros Therapeutics, Inc. (KROS) (SEC CIK 1664710), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Keros Therapeutics, Inc.
Ask AI about KROS filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting KROS positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on KROS.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Keros Therapeutics, Inc. (KROS) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Aug 3, 2026 | - | - | - |
8-K | Aug 3, 2026 | - | - | - |
8-K | Jul 30, 2026 | - | - | - |
8-K | Jul 22, 2026 | - | - | - |
8-K | Jun 25, 2026 | - | - | - |
8-K | Jun 3, 2026 | - | - | |
8-K | Jun 1, 2026 | - | - | |
10-Q | May 14, 2026 | Mar 31, 2026 | - | |
8-K | May 14, 2026 | - | - | |
8-K | Mar 9, 2026 | - | Analysis | - |
10-K | Mar 4, 2026 | Dec 31, 2025 | - | |
8-K | Mar 4, 2026 | - | Analysis | - |
8-K | Mar 4, 2026 | - | Analysis | - |
8-K | Feb 26, 2026 | - | Analysis | - |
8-K | Feb 18, 2026 | - | - | |
8-K | Jan 9, 2026 | - | - | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | - | |
10-Q | May 6, 2025 | Mar 31, 2025 | - | |
10-K | Feb 26, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | - | |
10-Q | May 8, 2024 | Mar 31, 2024 | - | |
10-K | Feb 28, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate KROS share value held by 13F filers tracked by SignalX, by quarter.
- Dimensional Fund Advisors+263.3K (+454%)
- AQR Capital Management+226.0K (+125%)
- BlackRock+121.3K (+5%)
- Wells Fargo & Co+118.3K (+361%)
- Two Sigma Investments+45.4K (+14%)
- State Street Corp514.3K (-48%)
- Goldman Sachs Group366.0K (-62%)
- D.E. Shaw & Co245.9K (-33%)
- Citadel Advisors LLC144.4K (-21%)
- Renaissance Technologies LLC138.2K (-23%)
- Principal Financial Group+59.6K
- Franklin Resources+21.8K
- Vanguard Group Inc−1.53M
- Invesco Ltd−87.4K
- JPMorgan Chase & Co−18.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 159 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest KROS SEC filings in 2026?
Keros Therapeutics, Inc. (KROS) has filed a 10-K annual report on March 4, 2026, a 10-Q quarterly report on May 14, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did KROS file its most recent 10-K annual report?
Keros Therapeutics, Inc. (KROS) filed its most recent 10-K annual report on March 4, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view KROS 10-Q quarterly reports?
Keros Therapeutics, Inc. (KROS)'s most recent 10-Q quarterly report was filed on May 14, 2026. SignalX displays every KROS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has KROS filed recently?
Keros Therapeutics, Inc. (KROS)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find KROS insider trading activity (Form 4)?
SignalX aggregates every KROS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does KROS file with the SEC?
Keros Therapeutics, Inc. (KROS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KROS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Keros Therapeutics, Inc. (KROS).
What is KROS's SEC CIK number?
Keros Therapeutics, Inc. (KROS)'s SEC CIK (Central Index Key) number is 1664710. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1664710 to look up all KROS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Keros Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 49+ filings.